Business Description
Theriva Biologics Inc
NAICS : 325412
SIC : 2834
ISIN : US87164U1025
Description
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 9.44 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.08 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 36.8 | |||||
| 3-Year EPS without NRI Growth Rate | 44.3 | |||||
| 3-Year FCF Growth Rate | 42.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 43.94 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 9-Day RSI | 16.15 | |||||
| 14-Day RSI | 21.91 | |||||
| 6-1 Month Momentum % | -56.98 | |||||
| 12-1 Month Momentum % | -75.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.67 | |||||
| Quick Ratio | 2.67 | |||||
| Cash Ratio | 2.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -80.3 | |||||
| Shareholder Yield % | 6.09 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -78.51 | |||||
| ROA % | -53.82 | |||||
| ROIC % | -76.74 | |||||
| 3-Year ROIIC % | -34.26 | |||||
| ROC (Joel Greenblatt) % | -1052.51 | |||||
| ROCE % | -49.6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.15 | |||||
| Price-to-Tangible-Book | 0.63 | |||||
| EV-to-EBIT | 0.5 | |||||
| EV-to-EBITDA | 0.51 | |||||
| EV-to-FCF | 0.56 | |||||
| Price-to-Net-Current-Asset-Value | 0.93 | |||||
| Price-to-Net-Cash | 4.03 | |||||
| Earnings Yield (Greenblatt) % | 200 | |||||
| FCF Yield % | -466.99 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Theriva Biologics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -30.469 | ||
| Beta | 0.76 | ||
| Volatility % | 71.36 | ||
| 14-Day RSI | 21.91 | ||
| 14-Day ATR (€) | 0.000148 | ||
| 20-Day SMA (€) | 2.42 | ||
| 12-1 Month Momentum % | -75.31 | ||
| 52-Week Range (€) | 2.42 - 12.625 | ||
| Shares Outstanding (Mil) | 2.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Theriva Biologics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Theriva Biologics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Theriva Biologics Inc Frequently Asked Questions
What is Theriva Biologics Inc(FRA:SFY0)'s stock price today?
The current price of FRA:SFY0 is €2.42. The 52 week high of FRA:SFY0 is €12.63 and 52 week low is €2.42.
When is next earnings date of Theriva Biologics Inc(FRA:SFY0)?
The next earnings date of Theriva Biologics Inc(FRA:SFY0) is 2025-03-25 Est..
Does Theriva Biologics Inc(FRA:SFY0) pay dividends? If so, how much?
Theriva Biologics Inc(FRA:SFY0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers